Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-04-18 1:32 pm Purchase | 2022-04-11 | 13G | Trevi Therapeutics, Inc. TRVI | Frazier Life Sciences Public Fund, L.P. | 3,816,459 10.000% | 3,816,459 (New Position) | Filing History |
| 2022-03-29 4:23 pm Purchase | 2022-03-24 | 13G | Sierra Oncology, Inc. SRRA | Frazier Life Sciences Public Fund, L.P. | 2,366,853 10.000% | 1,562,186 (+194.14%) | Filing History |
| 2022-03-17 12:42 pm Purchase | 2022-03-10 | 13G | Gracell Biotechnologies Inc. GRCL | Frazier Life Sciences Public Fund, L.P. | 17,104,865 5.100% | 17,104,865 (New Position) | Filing History |
| 2022-03-01 2:40 pm Purchase | 2022-02-24 | 13G | Cogent Biosciences, Inc. COGT | Frazier Life Sciences Public Fund, L.P. | 2,188,004 11.000% | 2,188,004 (New Position) | Filing History |
| 2022-01-31 5:00 pm Purchase | 2022-01-26 | 13D | KalVista Pharmaceuticals, Inc. KALV | Frazier Life Sciences Public Fund, L.P. | 1,572,192 6.400% | 303,463 (+23.92%) | Filing History |
| 2022-01-28 1:41 pm Purchase | 2021-12-31 | 13G | Pardes Biosciences, Inc. PRDS | Frazier Life Sciences Public Fund, L.P. | 2,457,507 3.900% | 2,457,507 (New Position) | Filing History |
| 2022-01-28 1:39 pm Purchase | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Frazier Life Sciences Public Fund, L.P. | 1,505,200 6.900% | 200,000 (+15.32%) | Filing History |
| 2021-12-30 4:33 pm Purchase | 2021-12-21 | 13D | KalVista Pharmaceuticals, Inc. KALV | Frazier Life Sciences Public Fund, L.P. | 1,268,729 5.200% | 1,268,729 (New Position) | Filing History |
| 2021-12-23 5:28 pm Purchase | 2021-12-20 | 13G | Syndax Pharmaceuticals, Inc. SNDX | Frazier Life Sciences Public Fund, L.P. | 2,772,062 5.600% | 2,772,062 (New Position) | Filing History |
| 2021-12-17 2:37 pm Purchase | 2021-12-13 | 13G | Autolus Therapeutics plc AUTL | Frazier Life Sciences Public Fund, L.P. | 3,730,657 5.100% | 3,730,657 (New Position) | Filing History |
| 2021-12-17 2:36 pm Purchase | 2021-12-07 | 13G | FS Development Corp. II FSII | Frazier Life Sciences Public Fund, L.P. | 1,113,700 5.400% | 1,113,700 (New Position) | Filing History |
| 2021-09-21 3:36 pm Purchase | 2021-09-17 | 13G | GRITSTONE BIO INC GRTSQ | Frazier Life Sciences Public Fund, L.P. | 4,728,551 8.700% | 4,728,551 (New Position) | Filing History |
| 2021-08-26 12:56 pm Purchase | 2021-08-16 | 13G | Viridian Therapeutics, Inc. VRDN | Frazier Life Sciences Public Fund, L.P. | 1,305,200 13.600% | 1,305,200 (New Position) | Filing History |
| 2021-08-16 4:17 pm Purchase | 2021-08-06 | 13G | Sierra Oncology, Inc. SRRA | Frazier Life Sciences Public Fund, L.P. | 804,667 9.500% | 804,667 (New Position) | Filing History |